临床病理沟通.pptVIP

* HL: the role of microenvironment HRS T B B Cell component (CD 20 expression) 20% -70% * Rituximab Treatment of Hodgkin Disease MDACC Stanford Germany The Target Normal B cells Tumor cells Tumor cells Eligibility Relapsed New or Relapsed Relapsed LP NS or MC LP or CD20+ NS/ MC Dose/Schedule 375 mg/m2 375 mg/m2 375 mg/m2 Weekly x 6 Weekly x 4 Weekly x 4 Evaluable (N) 22 22 14 (10 LP) CR 1 10 8 PR 4 12 4 Overal RR 23% 100% 86% 谢 谢 Subcutaneous panniculitis-like T-cell lymphoma WHO分类原则 细胞谱系是疾病定义的出发点 B、T或 NK 细胞 每种疾病都是具有临床和实验室特征的独立实体 形态学 免疫表型